Association of New Use of Antihypertensives That Stimulate vs Inhibit Type 2 and 4 Angiotensin II Receptors With Dementia Among Medicare Beneficiaries (Marcum, JAMA Open Network 2022)
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
This week, we will discuss an old dilemma in nephrology. To restrict or supplement the proteins? Premise: advanced CKD and dialysis.
This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.
Association of New Use of Antihypertensives That Stimulate vs Inhibit Type 2 and 4 Angiotensin II Receptors With Dementia Among Medicare Beneficiaries (Marcum, JAMA Open Network 2022)